Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genor Biopharma Holdings Limited ( (HK:6998) ) has provided an update.
Edding Genor Group Holdings Limited has announced the current composition of its board of directors, listing executive, non-executive and independent non-executive directors, including Ni Xin and Zhai Jing as executive directors. The company also disclosed the membership and chairmanship roles across its three key board committees—audit, compensation and nomination—clarifying oversight responsibilities and governance structure, which may enhance transparency and strengthen corporate governance for shareholders and other stakeholders.
More about Genor Biopharma Holdings Limited
Edding Genor Group Holdings Limited, formerly known as Genor Biopharma Holdings Limited, is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange (Stock Code: 6998). The company operates in the biopharmaceutical sector, focusing on the research, development and commercialization of innovative therapies, with a primary market focus in Greater China and other global markets.
YTD Price Performance: 76.30%
Average Trading Volume: 813,079
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.61B
Find detailed analytics on 6998 stock on TipRanks’ Stock Analysis page.